Risk factors
Penumbra (PEN) risk factors
Item 1A of every Penumbra Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors60 risks8 new2 dropped6 reworded
The company entered into an agreement to be acquired by Boston Scientific Corporation for $374 per share, dominating the new risk disclosures.
Filed Feb 25, 2026 - FY2024 10-K risk factors54 risks
Penumbra faces intense medical device competition, reliance on key product families, pricing pressures from GPOs, and stringent FDA and foreign regulations.
Filed Feb 18, 2025